Amgen Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Biotechnology | Market Cap: ₹1.8L Cr
- Amgen expects 2026 to be a "springboard year" for future growth, with rapidly growing products offsetting patent expirations and competition. - Amgen expects 2026 to be a "springboard year" for future growth, driven by rapidly growing products offsetting patent expirations and competition.
From Amgen Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹336.48
Market Cap
₹1.8L Cr
P/E Ratio
23.4
Revenue Rank
Margin Rank
How does Amgen Inc. rank in Biotechnology?
Compare Amgen Inc. against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Amgen expects 2026 to be a "springboard year" for future growth, with rapidly growing products offsetting patent expirations and competition.
- →Guidance for 2026 revenue raised to $37.1 billion to $38.5 billion.
- →Non-GAAP earnings per share guidance raised to $21.70 to $23.10.
- →Six key growth drivers (including Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, biosimilars) generated 70% of sales and grew 24% year-over-year.
- →Biosimilars have generated more than $14 billion cumulatively since 2018, contributing meaningful growth and expanding patient access.
- →Continued investment in pipeline, particularly MariTide, IMDELLTRA, and Olpasiran, with increased R&D spending by 16% year-over-year.
- →Strong first quarter performance with free cash flow of $1.5 billion and product sales growth of 4%.
- →Innovation pipeline and AI integration expected to deliver sustained long-term growth.
📈 Profitability & Margins
Rank 3- →Amgen expects 2026 to be a "springboard year" for future growth, driven by rapidly growing products offsetting patent expirations and competition.
- →Raised 2026 guidance ranges for revenue ($37.1B to $38.5B) and non-GAAP earnings per share (EPS) between $21.70 and $23.10.
- →Non-GAAP operating margin for 2026 is expected to be roughly 45% to 46% of product sales, consistent with Q1 performance.
- →Non-GAAP operating income and expenses projected at $2.2B to $2.3B for 2026.
- →Non-GAAP tax rate expected in the range of 15.0% to 16.5%.
- →Free cash flow showed $1.5 billion in Q1, supporting continued investments and shareholder returns.
- →Investments in pipeline innovation and manufacturing capacity (including for MariTide launch) prioritized to sustain long-term growth.
🏗️ Capital Expenditure Plans
Yes- →Amgen invested $700 million in capital expenditures in Q1 2026, focused on U.S. manufacturing sites in Ohio, North Carolina, and Puerto Rico.
- →Full-year 2026 capital expenditures are expected to be approximately $2.6 billion.
- →These investments aim to scale manufacturing capacity to support volume growth, including for the upcoming launch of MariTide.
- →The company continues to invest significantly in advancing its late-stage pipeline, including MariTide, IMDELLTRA, and Olpasiran.
- →Emphasis on technology and AI to enhance productivity and operational efficiency across the enterprise, such as AI reducing production line clearance from 30 to 2 minutes per batch.
- →Continued investment in innovation and clinical development aligns with long-term growth and strategic objectives.
💰 Fundraising & Capital Structure
No information- →The call does not mention any current or planned new fundraising through debt or equity.
- →In Q1, Amgen incurred $480 million of non-GAAP OI&E expenses, including a $90 million gain from retiring debt via open market repurchases, indicating some debt reduction activity.
- →The company expects share repurchases not to exceed $3 billion in 2026, showing capital return to shareholders rather than equity issuance.
- →Guidance does not include any potential business development transactions that may occur in the remainder of the year, but no explicit mention of raising capital.
- →Overall, Amgen appears focused on investing internal cash flow and managing existing financial obligations without announcing new debt or equity fundraising in this call.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Amgen Inc. Q2 FY26 results?
- Amgen expects 2026 to be a "springboard year" for future growth, with rapidly growing products offsetting patent expirations and competition. - Amgen expects 2026 to be a "springboard year" for future growth, driven by rapidly growing products offsetting patent expirations and competition.
What is Amgen Inc. share price analysis?
Amgen Inc. currently shows a below-average growth signal. The stock trades at a P/E of 23.4 with a market cap of $181,601. Investors should review the full earnings analysis for detailed insights.
Is Amgen Inc. planning capital expenditure?
- Amgen invested $700 million in capital expenditures in Q1 2026, focused on U.S.
Keep Amgen Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.